Effect of Broccoli Sprouts Homogenate on SS RBC

Completed · Not applicable

Conditions studied: Sickle Red Blood Cell, Fetal Hemoglobin, Oxidative Stress

In brief

The overall purpose of this study is to obtain a better understanding of the biological response of red blood cells to sulforaphane contained in fresh broccoli sprouts that have been put through a blending process. This study will use commercially available fresh broccoli sprouts certified by Brassica Protection Products LLC (BroccoSprouts®). This product can also be purchased at some local grocery stores in the produce section. It is believed that NRF2, a transcription factor encoded by the NFE2L2 gene, plays a role in the regulation of defense against oxidative stress. The detrimental accelerated breakdown of sickle cell disease (SCD) red blood cells (SS RBC) is partially due to reduced anti-oxidative capacity. Previous analysis of SS RBC microRNAs revealed that a reduced level of NRF2, the master regulator of anti-oxidative stress capacity, contributes to reduced resistance to oxidative stress and increased hemolysis; NRF2 also induces fetal hemoglobin (HbF), which is known to prevent SS RBC sickling. First, erythroid progenitors from normal and SCD subjects will be tested ex-vivo to find out how sulforaphane, a natural NRF2 activator, affects the oxidative stress capacity, HbF expression, and microRNA expression of red cells. Second, a pilot clinical trial will be conducted to determine the safety and physiological effects of 3 weeks of daily consumption of broccoli sprout homogenate in a cohort of Hb SS/SB0 thalassemia adult SCD patients. During this study, subjects RBCs will be assayed for changes in anti-oxidative stress capacity and microRNA composition in mature SCD red blood cells.

Key facts

Study ID

NCT01715480

Run by

Duke University

People needed

21

Starts

2012-03-01

Expected to finish

2015-04-01

Last updated by the study team

2015-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of Hemoglobin (Hb) SS or Hb Sβ0 thalassemia by electrophoresis
• Age ≥18 years
• Hematocrit (Hct) ≥ 20% and Hb > 6.0 g/dL
• Capacity to understand and sign informed consent and can adhere to the daily regimen of BSH

You may not qualify if…

• RBC transfusion or change in hydroxyurea dose during the 3 months prior to study entry
• Ongoing pregnancy
• Diabetes
• Renal insufficiency (BUN >21 mg/dL and/or Creatinine >1.4 mg/dL)
• History of allergy to sulfonamides

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.